Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 5/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | PLAT | P00750 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10181250 | 0.91 | TP53 (0.50) | TP53POLBDPP4DPP7NPC1 | |
| SCHEMBL3763721 | 0.88 | TP53 (0.57) | TP53POLBNPC1RAB9AGAA | |
| SCHEMBL10181241 | 0.86 | TP53 (0.53) | TP53POLBDPP4DPP7NPC1 | |
| SCHEMBL3755998 | 0.86 | TP53 (0.55) | TP53POLBNPC1RAB9ATSHR | |
| SCHEMBL3758569 | 0.84 | TP53 (0.53) | TP53POLBNPC1RAB9AGAA | |
| SCHEMBL3756749 | 0.79 | TP53 (0.60) | TP53NPC1RAB9AGAASMN1; SMN2 | |
| SCHEMBL3751207 | 0.79 | TP53 (0.52) | TP53POLBNPC1RAB9ALMNA | |
| SCHEMBL10179764 | 0.79 | TP53 (0.49) | TP53POLBDPP4DPP7NPC1 | |
| SCHEMBL3748532 | 0.78 | TP53 (0.58) | TP53 | |
| SCHEMBL13765446 | 0.77 | TP53 (0.52) | TP53NPC1RAB9AGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202856-B2 | Triazole oxadiazoles derivatives | MERCK SERONO SA (CH) | 2012-06-19 | — | — | US | disclosed |
| US-8202856-B2 | Triazole oxadiazoles derivatives | MERCK SERONO SA (CH) | 2012-06-19 | — | — | US | disclosed |
| US-20100305092-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | MERCK SERONO SA (CH) | 2010-12-02 | — | — | US | disclosed |
| US-20100305092-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | MERCK SERONO SA (CH) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305092-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | OXA1L, RO60, PDCD11 | TP53 2220/4885POLB 2012/4885DPP4 2346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.